Revision of PRECAUTIONS
Brimonidine tartrate/timolol maleate

June 11, 2024

Therapeutic category
Agents for ophthalmic use

Non-proprietary name
Brimonidine tartrate/timolol maleate

Safety measure
PRECAUTIONS should be revised.
<table>
<thead>
<tr>
<th>Current</th>
<th>Revision</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. IMPORTANT PRECAUTIONS</td>
<td>8. IMPORTANT PRECAUTIONS</td>
</tr>
<tr>
<td>(N/A)</td>
<td>Corneal opacity with neovascularisation, etc. may occur following administration of this drug. Patients should consult their doctor periodically, and they should be carefully monitored. In addition, they should be adequately instructed to seek medical attention immediately if they have any subjective symptoms such as hyperaemia, reduced visual acuity, or blurred vision.</td>
</tr>
</tbody>
</table>

11. ADVERSE REACTIONS

11.1 Clinically Significant Adverse Reactions

(N/A) | 11.1 Clinically Significant Adverse Reactions

[Corneal opacity]

[References]

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.